


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

**Note:** Consider clinical trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a comprehensive cancer center.

## PATIENT PRESENTATION<sup>2</sup>

## TREATMENT

## SURVEILLANCE



IPSS = International Prognostic Scoring System  
 IPSS-R = revised International Prognostic Scoring System

<sup>1</sup> Age ≥ 18 years

<sup>2</sup> See [Physical Activity](#), [Nutrition](#), and [Tobacco Cessation](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

<sup>3</sup> MDS risk is calculated utilizing the IPSS or IPSS-R score, which includes percent of blast, cytogenetics (consider [MD Anderson approved biomarkers](#)), and number of cytopenias

<sup>4</sup> See [Leukemia Clinical Trials](#)

<sup>5</sup> GCC should be initiated by the Primary Oncologist. If Primary Oncologist is unavailable, Primary Team/Attending Physician to initiate GCC discussion and notify Primary Oncologist. Patients, or if clinically indicated, the Patient Representative should be informed of therapeutic and/or palliative options. GCC discussion should be consistent, timely, and re-evaluated as clinically indicated. The Advance Care Planning (ACP) note should be used to document GCC discussion. Refer to [GCC home page](#) (for internal use only).

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## SUGGESTED READINGS

- Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., & Parker, J. (2003). Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. *British Journal of Haematology*, 120(2), 187-200. <https://doi.org/10.1046/j.1365-2141.2003.03907.x>
- Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., . . . Silverman, L. R. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. *The Lancet Oncology*, 10(3), 223-232. [https://doi.org/10.1016/S1470-2045\(09\)70003-8](https://doi.org/10.1016/S1470-2045(09)70003-8)
- Fenaux, P., Platzbecker, U., Mufti, G. J., Garcia-Manero, G., Buckstein, R., Santini, V., . . . List, A. F. (2020). Luspatercept in patients with lower-risk myelodysplastic syndromes. *The New England Journal of Medicine*, 382(2), 140-151. <https://doi.org/10.1056/nejmoa1908892>
- Kantarjian, H., Issa, J. P. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., Dipersio, J., . . . Saba, H. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. *Cancer*, 106(8), 1794-1803. <https://doi.org/10.1002/cncr.21792>
- List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., . . . Knight, R. (2006). Lenalidomide in the myelodysplastic syndrome with Chromosome 5q deletion. *The New England Journal of Medicine*, 355(14), 1456-1465. <https://doi.org/10.1056/NEJMoa061292>
- MD Anderson Institutional Policy #CLN1202 - Advance Care Planning Policy  
Advance Care Planning (ACP) Conversation Workflow (ATT1925)
- Mufti, G. J., Bennett, J. M., Goasguen, J., Bain, B. J., Baumann, I., Brunning, R., . . . Yoshimi, A. (2008). Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. *Haematologica*, 93(11), 1712-1717. <https://doi.org/10.3324/haematol.13405>
- National Comprehensive Cancer Network. (2022). *Myelodysplastic Syndromes* (NCCN Guideline Version 1.2023). Retrieved from [https://www.nccn.org/professionals/physician\\_gls/pdf/mds.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf)
- Oliansky, D. M., Antin, J. H., Bennett, J. M., Joachim Deeg, H., Engelhardt, C., Heptinstall, K. V., . . . Hahn, T. (2009). The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: An evidence-based review. *Biology of Blood and Marrow Transplantation*, 15(2), 137-172. <https://doi.org/10.1016/j.bbmt.2008.12.003>
- Santini, V., Alessandrino, P. E., Angelucci, E., Barosi, G., Billio, A., Di Maio, M., . . . Tura, S. (2010). Clinical management of myelodysplastic syndromes: Update of SIE, SIES, GITMO practice guidelines. *Leukemia Research*, 34(12), 1576-1588. <https://doi.org/10.1016/j.leukres.2010.01.018>
- Tefferi, A., & Vardiman, J. W. (2009). Myelodysplastic syndromes. *The New England Journal of Medicine*, 361(19), 1872-1885. <https://doi.org/10.1056/NEJMra0902908>
- Valent, P., Horny, H. P., Bennett, J. M., Fonatsch, C., Germing, U., Greenberg, P., . . . Wells, D. A. (2007). Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. *Leukemia Research*, 31(6), 727-736. <https://doi.org/10.1016/j.leukres.2006.11.009>

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Leukemia Center Faculty workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

### Core Development Team Leads

Alessandra Ferrajoli, MD (Leukemia)  
Guillermo Garcia-Manero, MD (Leukemia)  
Hagop Kantarjian, MD (Leukemia)

### Workgroup Members

Yesid Alvarado, MD (Leukemia)	Steven Kornblau, MD (Leukemia)
Michael Andreeff, PhD, MD (Leukemia)	Lucia Masarova, MD (Leukemia)
Kapil Bhalla, MD (Leukemia)	Deborah McCue, PharmD (Pharmacy Clinical Programs)
Gautam Borthakur, MBBS (Leukemia)	Guillermo Montalban-Bravo, MD (Leukemia)
Prithviraj Bose, MD (Leukemia)	Maro Ohanian, DO (Leukemia)
Jan Burger, MD (Leukemia)	Naveen Pemmaraju, MD (Leukemia)
Naval Daver, MD (Leukemia)	Farhad Ravandi-Kashani, MD (Leukemia)
Courtney DiNardo, MD (Leukemia)	Koji Sasaki, MD (Leukemia)
Wendy Garcia, BS <sup>♦</sup>	Nicholas Short, MD (Leukemia)
Ghayas Issa, MD (Leukemia)	Koichi Takahashi, MD (Leukemia)
Elias Jabbour, MD (Leukemia)	Philip Thompson, MBBS (Leukemia)
Nitin Jain, MBBS (Leukemia)	Srdan Verstovsek, MD (Leukemia)
Tapan Kadia, MD (Leukemia)	Mary Lou Warren, DNP, APRN, CNS-CC <sup>♦</sup>
Michael Keating, MD (Leukemia)	William Wierda, PhD, MD (Leukemia)
Marina Konopleva, PhD, MD (Leukemia)	Musa Yilmaz, MD (Leukemia)

<sup>♦</sup> Clinical Effectiveness Development Team